Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination Therapy Trial Using an Adaptive Platform Design for Children and Young Adults With Diffuse Midline Gliomas (PNOC022)
NCT05009992Phase 2Recruiting
- Sponsor
- University of California, San Francisco
- Start
- Oct 2021
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 6
01
Overview
A Phase 2 trial of dordaviprone in diffuse midline glioma (DMG), diffuse intrinsic pontine glioma (DIPG), sponsored by University of California, San Francisco. Started Oct 2021; status: recruiting.
02
Drugs
dordaviprone
03
Conditions
diffuse midline glioma (DMG)diffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on NCT05009992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05009992.